Intermountain Health Care Custom Case Solution & Analysis

1. Business Case Data Researcher: Evidence Brief

The following data points are extracted directly from the Intermountain Health Care case study and associated exhibits. All figures are sourced from the internal Intermountain records as of the late 1990s.

Financial Metrics

Operational Facts

• Facility Count: 21 hospitals and over 100 clinics operating across Utah and southeastern Idaho. (Operational Overview)
• Physician Workforce: Approximately 400 physicians employed via the Intermountain Medical Group; 2100 additional physicians maintain affiliated status. (Personnel Records)
• Information Systems: The HELP (Health Evaluation through Logical Processing) system serves as the primary electronic medical record and clinical decision support tool. (IT Infrastructure Section)
• Clinical Management: 40 identified clinical programs targeting high-volume, high-cost, or high-risk medical conditions. (Clinical Strategy Document)

Stakeholder Positions

• Bill Nelson (CEO): Committed to the mission of clinical quality but concerned with the financial sustainability of the organization under current reimbursement models.
• Dr. Brent James (Executive Director): Advocates for the elimination of clinical variation through data-driven protocols. Maintains that quality improvement is the primary driver of cost reduction.
• Affiliated Physicians: Express concern regarding loss of clinical autonomy and the potential for standardized care to become cookbook medicine.
• Payers: Benefit from the reduced costs generated by Intermountain efficiencies without necessarily sharing those savings back with the provider.

Information Gaps

• Specific cost-per-case data for competitors in the Salt Lake City market is not provided.
• The exact percentage of revenue derived from capitated versus fee-for-service contracts is not explicitly stated.
• Longitudinal data on physician retention rates following the implementation of Care Process Models is absent.

2. Market Strategy Consultant: Strategic Analysis

Core Strategic Question

How can Intermountain Health Care align its internal clinical efficiencies with an external financial environment that rewards volume over value? The central dilemma involves the financial penalty Intermountain incurs when it improves patient health and reduces the number of medical interventions.

Structural Analysis

Value Chain Analysis: The Intermountain value chain is highly optimized at the clinical delivery stage. By using Care Process Models (CPMs), the organization reduces waste and improves outcomes. However, the downstream capture of this value is broken. In a fee-for-service model, every avoided test or shortened hospital stay represents lost revenue. The organization is currently more efficient than the market requires, leading to a situation where it subsidizes payers through its own operational excellence.

Competitive Positioning: Intermountain holds a dominant market share in its primary geography. This scale allows it to dictate clinical standards but also makes it a target for payers who seek to capture the savings Intermountain generates. The competitive advantage is currently clinical, not yet fully commercial.

Strategic Options

• Option 1: Aggressive Transition to Risk-Bearing Contracts. Intermountain should shift its payer mix toward full capitation or shared-savings models. This aligns the financial reward with the clinical goal of reducing medical utilization.
  Trade-off: Requires significant actuarial capabilities and shifts financial risk from the insurer to the provider.
• Option 2: Commercialization of Clinical Intellectual Property. Package the HELP system and the Care Process Models as a standalone software and consultancy business for other health systems.
  Trade-off: May dilute management focus and requires a different set of organizational competencies.
• Option 3: Selective Clinical Standardization. Focus standardization efforts only on areas where the cost savings directly offset revenue loss or where Intermountain is the payer through its own insurance arm.
  Trade-off: Compromises the clinical mission and creates a bifurcated care standard.

Preliminary Recommendation

Intermountain must pursue Option 1. The organization has already mastered the most difficult part of healthcare: process control. To sustain this, the business model must mirror the clinical model. By becoming the insurer or dominant risk-holder, Intermountain converts every dollar of saved clinical cost into a dollar of profit.

3. Operations and Implementation Planner: Implementation Roadmap

Critical Path

The transition to a risk-adjusted model requires immediate synchronization between clinical data and financial contracting. The sequence is as follows:

• Phase 1: Actuarial Integration (Months 1-3). Connect the clinical outcome data from the HELP system with financial billing data to determine the exact cost-to-treat for every Care Process Model.
• Phase 2: Payer Negotiation (Months 4-6). Initiate contract renewals with major payers to move from per-diem or fee-for-service to bundled payments or capitated rates based on Intermountain clinical benchmarks.
• Phase 3: Physician Incentive Realignment (Months 6-12). Redesign the compensation structure for the Intermountain Medical Group to reward clinical adherence and outcome metrics rather than patient volume.

Key Constraints

• Physician Cultural Resistance: Standardized protocols are often viewed as a threat to professional judgment. Implementation will fail if physicians feel they are losing the ability to customize care for complex patients.
• Information Technology Legacy: While the HELP system is advanced, it was designed for clinical support, not necessarily for complex risk-based financial modeling. Technical debt may slow the integration of actuarial tools.
• Revenue Cannibalization: During the transition period, Intermountain will experience a revenue dip as it reduces volume before the new risk-based contracts are fully active.

Risk-Adjusted Implementation Strategy

To mitigate the risk of financial instability, the rollout must be phased by clinical program. Start with high-volume, high-predictability areas like labor and delivery or elective orthopedic surgery. These areas provide the stable data sets needed to prove the financial model before moving into more volatile areas like oncology or emergency medicine. Contingency funds must be set aside to support departments that experience rapid volume declines during the transition.

4. Senior Partner and Executive Reviewer: Executive Review and BLUF

BLUF (Bottom Line Up Front)

Intermountain Health Care has achieved a level of clinical process control that is unique in the industry. However, the organization is currently a victim of its own success. By reducing clinical variation and waste, Intermountain is effectively reducing its own revenue under the prevailing fee-for-service model. The current path is unsustainable. Intermountain must aggressively pivot to a capitated, risk-bearing financial structure. This shift will allow the organization to capture the financial value of its clinical excellence. The transition is not merely an operational improvement but a fundamental necessity for long-term institutional survival. Approved for leadership review.

Dangerous Assumption

The most consequential unchallenged premise is that the existing payer market in Utah will willingly transition to capitated models. If payers recognize that Intermountain efficiency is reducing their total payout, they may resist any contract change that allows Intermountain to retain those savings. The analysis assumes Intermountain has sufficient market power to force this transition.

Unaddressed Risks

• Physician Attrition: There is a high probability that top-tier affiliated physicians will move their practices to competing systems that offer higher fee-for-service reimbursements and less clinical oversight. The consequence would be a loss of market share in high-margin specialty areas.
• Regulatory Scrutiny: Moving toward a dominant provider-payer model may trigger antitrust concerns or increased state regulatory oversight regarding insurance reserves and patient choice.

Unconsidered Alternative

The team failed to consider a divestiture strategy for the insurance arm. If Intermountain cannot achieve the necessary scale in its own insurance business to offset fee-for-service losses, it should consider selling the insurance entity and using the capital to double down on becoming a high-efficiency clinical wholesaler for other national insurers. This would avoid the risk-bearing burden while still utilizing the clinical data advantage.

MECE Assessment

• Mutually Exclusive: The strategic options presented represent distinct paths: risk-taking, IP commercialization, or selective standardization.
• Collectively Exhaustive: The analysis covers the clinical, financial, and operational dimensions of the problem, ensuring no major category of action is left unaddressed.

Verdict: APPROVED FOR LEADERSHIP REVIEW